Company: HURA
Filing Date: 2025-12-10
Form Type: 424B5
Source: 0001193125-25-313799
Chunk: 29

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-12-10
Form: 424B5
Chunk 29
---
 or if there are delays in obtaining, required regulatory approvals for our product candidates, we will not be able to commercialize, or 
 will be delayed in commercializing, such product candidates, and our ability to generate revenue will be materially impaired;                                                                                                                          |

| • |     | our ability to obtain or maintain patents or other appropriate protection for the intellectual property utilized 
 in our current and planned products; and                                                                         |

| • |     | our ability to develop and commercialize products without infringing the intellectual property rights of third 
 parties.                                                                                                       |

While we believe these expectations, assumptions, beliefs, estimates, projections, intentions, and strategies are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, most of which are difficult to predict and many of which are beyond our control. Actual results and timing of certain events may differ materially from those anticipated in these forward-looking statements as a 2

result of various factors. You should consider these factors carefully in evaluating forward-looking statements contained in this prospectus and the documents incorporated by reference into this
prospectus and are cautioned not to place undue reliance on such statements, which speak only as of the date of this prospectus. We undertake no obligation to update forward-looking statements, except as may be required under applicable securities
laws. See an additional discussion under the heading “Risk Factors” in this prospectus, in an applicable prospectus supplement and any related free writing prospectus, and in our most recent Annual Report on Form 10-K and any subsequently filed Quarterly Reports on Form 10-Q.

3

TUHURA BIOSCIENCES, INC.

The information contained in or incorporated by reference into this prospectus summarizes certain information about our company. It may not contain all of the information that is important to you. To understand this offering fully, you should read carefully the entire prospectus, including “Risk Factors,” and the other information incorporated by reference into this prospectus.

Overview

We are a
clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies.

Our proprietary Immune FxTM technology platform, or IFx, is an innate immune agonist technology designed to “trick” the
body’s immune system to attack tumor cells by making tumor cells look like bacteria. Our lead product candidate, IFx2.0, is an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. In June 2025